National Institute of Dental and Craniofacial Research (NIDCR)
National Institute of Dental and Craniofacial Research (NIDCR) sponsors 91 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 70 completed. 2 of these trials are in Phase 3-4 (later-stage) and 41 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Sjogren's Syndrome, with 6 trials.
Trial Pipeline
91 total, page 1 of 2
Safety and Efficacy of PTH-IA
NCT07541209
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren Disease
NCT07281456
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
NCT03602599
Natural History of Craniofacial Anomalies and Developmental Growth Variants
NCT02639312
Characterization of Diseases With Salivary Gland Involvement
NCT02327884
Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal
NCT01805869
Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)
NCT01568697
The Pathogenesis and Natural History of Sjogren's Disease
NCT01425892
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
NCT00804154
A Natural History Study of Bone and Mineral Disorders
NCT00024804
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
NCT00001727
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome
NCT04496960
Denosumab Treatment for Fibrous Dysplasia
NCT03571191
PTH-independent Effects of Encaleret
NCT05735015
Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia
NCT05509595
Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
NCT05419050
Transmissibility and Viral Load of SARS-CoV-2 in Oral Secretions
NCT04348240
BGJ398 for the Treatment of Tumor-Induced Osteomalacia
NCT03510455
Oral Health Needs Assessment of Sjogren s Syndrome and Salivary Gland Dysfunction Cohorts and Healthy Volunteers Evaluating Oral Health Disparities as Determinants of Oral Health in a High-Risk Population
NCT03327870
Bacterial Arrangement on the Teeth
NCT01712672
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
NCT01748812
Dexamethasone Irrigation of the Parotid Glands in Primary Sjögren's Syndrome Subjects
NCT01316770
Rapamycin Therapy in Head and Neck Squamous Cell Carcinoma
NCT01195922
The Molecular Anatomy of Oral Wound Healing
NCT01078467
Collection of Tissue Specimens for Analysis and Establishment of Cell Cultures
NCT00802607
Evaluation of the Role of the Autonomic Nervous System in Sj(SqrRoot)(Delta)Gren s Syndrome
NCT00565526
Procurement of Tissue Samples for Cell Cultures and Analyses
NCT00435877
Effects of PTH Replacement on Bone in Hypoparathyroidism
NCT00395538
Effect of AdhAQP1 on Salivary Flow in Patients Treated With Radiation for Head and Neck Cancer
NCT00372320
Physiologic Regulation of FGF-23
NCT00356512
Pilot Study of Raptiva to Treat Sjogren's Syndrome
NCT00344448
Diagnosis, Evaluation and Treatment of Patients in Need of Third Molar Removal
NCT00316485
Dexamethasone to Treat Oral Lichen Planus
NCT00111072
Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth
NCT00104026
Hydroxychloroquine vs. Clobetasol Rinse to Treat Oral Lichen Planus
NCT00102557
Stereo Photogrammetry Imaging in Normal Volunteers and Patients With Head and Facial Malformations
NCT00100529
Salivary Proteins in Disease and Health
NCT00100204
Catheterization to Locate Mesenchymal Tumors in Patients With Tumor-Induced Osteomalacia or Oncogenic Osteomalacia
NCT00099762
Collection of Dental Plaque and Saliva for Studies of Bacterial Colonization of Teeth
NCT00098267
Clinical Research Core Dental Screening Protocol
NCT00090818
Levels of Bisphenol A in Urine and Saliva Following Placement of Composite Restorations
NCT00339339
Capsaicin to Control Pain Following Third Molar Extraction
NCT00088686
Synvisc to Treat Osteoarthritis of the Temporomandibular Joint
NCT00078351
Pain Pathways in the Brain
NCT00078364
Prostanoid Levels After Medication to Prevent Pain Following Third Molar (Wisdom Tooth) Extraction
NCT00078104
Studying Phosphorus Metabolism
NCT00066183
Chemical and Genetic Effects of the Experimental Anti-Cancer Drugs in Cheek Cells in Cancer Patients
NCT00055380
Rofecoxib and Bupivacaine to Prevent Pain After Third Molar (Wisdom Tooth) Extraction
NCT00050362
Study of Oral Bacteria in Patients With Dry Mouth
NCT00048685
Magnets in the Treatment of Sciatica
NCT00044109
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 32 |
| Phase 3 | 2 |
Therapeutic Areas
What the Pipeline for National Institute of Dental and Craniofacial Research (NIDCR) Shows
According to the ClinicalTrials.gov registry, National Institute of Dental and Craniofacial Research (NIDCR) is linked to 91 US clinical trials across every stage of research activity. Of those, 11 studies are currently recruiting, about 12% of the sponsor's indexed portfolio, and 70 are already marked complete, representing roughly 77% of the total.
The phase mix for National Institute of Dental and Craniofacial Research (NIDCR) reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 41 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for National Institute of Dental and Craniofacial Research (NIDCR) is Sjogren's Syndrome with 6 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.